DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

DRG
  • Login
  • Products
    • Biopharma
      • Market Assessment
      • Multichannel Engagement Insights
      • Real-World Data
      • Market Access

      • Fingertip Formulary Suite
      • Managed Market Surveyor
      • Account Management Dashboard
      • U.S. Managed Markets Insights
      • Healthbase
      • Market Access Platform
      • Global Market Access Solution
    • Medtech
      • Market Insights
      • Procedure Finder
      • PriceTrack
  • Solutions
    • Solutions
      • Market Sizing and Forecasting
      • Commercial Effectiveness
      • Global Access Solutions
      • Multichannel Engagement Strategy
      • Integrated Patient Journey
      • Understanding Covered Lives
      • Learning Solutions
      • Biotech solutions
      • Medtech Solutions
      • Payer Solutions
      • Provider Solutions
    • Consulting Services
      • Consulting Services
      • HEOR & Value Communication
  • Find A Report
    • Market Assessment
    • Multichannel Engagement
    • Market Access
    • Medtech Insights
  • Events
    • Meet Us at These Events
  • DRG Perspectives
  • About Us
    • Our Company
    • About Clarivate
    • Newsroom
    • Careers
    • Contact us

DRG and its group companies would like to inform you that we have updated our website privacy policy.

Acknowledge
Home › DRG Perspectives › COVID-19 Market Impact Assessment:...
COVID-19 Market Impact Assessment
Gynecology
Published on: 20 April 2020
Last updated on: 20 July 2020


DRG’s Medtech Insights (Part of Clarivate) is actively assessing the impact of COVID-19 on all therapy areas and incorporating the impact into reports. This piece contains some therapy-specific highlights based on currently available information.

Gynecology
  • Impact Assessment Summary
  • Detailed Impact Information

    • Procedure Volumes and Unit Sales
    • Companies
    • Clinical Trials
    • Supply Chain
  • Guidelines/Recommendations

Impact Assessment Summary
Factors Initial Effect Expected 1yr Recovery Comments
Company Sales/Revenue Moderate Moderate Top competitors have reported a negative impact on revenues and are implementing measures to cut expenses
Procedure Volumes Moderate to Strong Moderate to Strong Some gynecological procedures, such as endometrial ablations, sterilizations, fibroid excisions, and PFRs, are considered nonessential and have been delayed; however, as earlier restrictions are now easing in a number of countries (or certain states, provinces, and cities), some procedures will be resumed
ASPs Weak Strong There may be slight impact on ASPs if companies choose to support sales volumes through discounts
New Product Launches Weak Moderate Because non-COVID-19 related research activities are being postponed, some product launches will be pushed until trial operations return to normal
Clinical Trials Moderate Moderate Nonessential trials will be deprioritized and paused/delayed to dedicate more resources to COVID-19.
Supply Chain Moderate Moderate Some disruptions in sourcing raw materials from impacted countries, such as China, were observed in early 2020, but such disruptions are unlikely to have a substantial impact going forward
*General guidance: Weak: 0-10% change in values/timelines; Moderate: 10-20% change in values/timelines; Strong: >20% change in values/timelines. DRG Medtech is developing a robust quantitative framework for our market forecasts; impact metrics shown here may change in the future to align with those used in the quantitative framework.

Detailed Impact Information
Procedure Volumes and Unit Sales
  • Elective and nonessential gynecological procedure volumes have been impacted significantly in the H1 2020; however, now that some countries (or states, cities, and provinces) have begun easing some restrictions, some gynecological procedures will be gradually resumed.
  • Gynecological procedures related to oncology, urinary incontinence, and pelvic organ prolapse are being evaluated on a case-by-case basis depending on the patient's condition.
  • Concerns have been raised surrounding the use of minimally invasive surgeries, especially by laparoscopic approaches, due to the possibility of aerosol formation during the procedure, which can infect the surgical staff. This will further limit procedure volumes and unit sales in this market.
Companies
  • Hologic has withdrawn its 2020 financial guidance and is expecting a decline in revenues in Q2 and Q3, due primarily to the postponement of elective surgeries. The company has implemented expense-reduction measures but is still in the process of discerning the true impact on its business.
  • Boston Scientific is also expecting Q3 revenues to decline due to deferred procedures and is expected to release final sales results on April 29, 2020.
  • Coloplast has similarly revised its financial guidance for 2020 and is now expecting slower revenue growth for Q2 and Q3, though the company expects to recapture sales once the situation normalizes.
Clinical Trials
  • The EMA and FDA have both released guidance to assess risk factors for clinical trials, effectively limiting recruitment for new trials and pausing some nonessential trials; ongoing trials for essential cases, such as those for oncology-related complications, will continue.
Supply Chain
  • KARL STORZ and Coloplast have indicated that their supply chains have not been disrupted and that they will continue operations to ensure supply availability as expected.

Guidelines/Recommendations Links
  • RCOG and Specialist Societies’ guidance for gynecological services
  • AAGL Joint statement on MIS and Gynecology procedures
  • COVID-19 Global Pandemic: Options for Management of Gynecologic Cancers

MedTech Executive Briefings

A look ahead: Medical aesthetics market recovery in 2021 and beyond

View Now
DRG

Decision Resources Group

DRG is the premier provider of healthcare analytics, data and insight products and services to the world’s leading pharma, biotech and medical technology companies.

Read More

Company

  • About DRG
  • Careers
  • Offices
  • Locations

Resources

  • Sitemap
  • Newsroom
  • Whitepapers
  • Events
  • Reports

Support

  • Client Portal

Social

  • Linkedin
  • Facebook
  • Twitter
  • Youtube
  • Contact Us
  • Privacy & Cookies
  • Term of Use
  • Privacy Center
  • 2020 DR/Decision Resources, LLC
  • Find a Report
  • Linkedin
  • Twitter
  • Contact Us
Thank you for your ebook download,
and live webinar registration.

Don’t forget to attend on Jan. 19!

Close